{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:16:38Z","timestamp":1773242198726,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"6P2","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4247,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2000,6]]},"abstract":"<jats:p><jats:bold>Study Objectives.<\/jats:bold> To assess the safety and pharmacokinetics of oral gatifloxacin 400 mg in subjects with and without hepatic impairment, and the need to modify doses in patients with hepatic dysfunction.<\/jats:p><jats:p><jats:bold>Design.<\/jats:bold> Single\u2010dose, nonrandomized, open\u2010label, parallel\u2010group study.<\/jats:p><jats:p><jats:bold>Setting.<\/jats:bold> Clinical Research Center, New Orleans, Louisiana.<\/jats:p><jats:p><jats:bold>Patients.<\/jats:bold> Eight subjects with grade B or C hepatic dysfunction (Child\u2010Pugh classification) and eight age\u2010, weight\u2010, and gender\u2010matched subjects with normal hepatic function.<\/jats:p><jats:p><jats:bold>Interventions.<\/jats:bold> After a single oral dose of gatifloxacin 400 mg, blood and urine samples were collected at specified times or intervals over 48 hours to determine drug concentrations.<\/jats:p><jats:p><jats:bold>Measurements and Main Results.<\/jats:bold> All 16 subjects (7 with grade B and 1 with grade C hepatic impairment, 8 with normal hepatic function) completed the study. Peak plasma concentration (C<jats:sub>max<\/jats:sub>) and area under the plasma concentration\u2010time curve (AUC<jats:sub>0\u2013\u221e<\/jats:sub>) for gatifloxacin were 32% and 22% higher, respectively, in subjects with hepatic impairment. Except for C<jats:sub>max<\/jats:sub>, the ratio of means for AUC satisfied the specified criterion (0.67\u20131.50) for lack of effect. There were no statistically significant differences in any other pharmacokinetic values except apparent oral clearance (Cl<jats:sub>T<\/jats:sub>\/F). All treatment\u2010emergent adverse events were mild or moderate in intensity and resolved before subjects were discharged from the study.<\/jats:p><jats:p><jats:bold>Conclusion.<\/jats:bold> Modest increases in Cmax and AUC<jats:sub>0\u2013\u221e<\/jats:sub> are not anticipated to have a negative effect on the outcome of therapy in hepatically impaired subjects, nor are they anticipated to result in adverse drug reactions. Patients with moderate to severe (Child\u2010Pugh grade B or C) hepatic dysfunction do not require gatifloxacin dose adjustments. In addition, the similarity in half\u2010life (t<jats:sub>1\/2<\/jats:sub>) for the groups (8.9 hrs for hepatically impaired subjects, 9.3 hrs for controls) suggests that no difference would be anticipated in the extent of drug accumulation after multiple doses. The overall safety and tolerability of a single oral dose of gatifloxacin 400 mg were excellent in both healthy subjects and those with hepatic impairment.<\/jats:p>","DOI":"10.1592\/phco.20.8.87s.35187","type":"journal-article","created":{"date-parts":[[2004,6,16]],"date-time":"2004-06-16T07:41:04Z","timestamp":1087371664000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Safety and Pharmacokinetics of a Single Oral Dose of Gatifloxacin in Patients with Moderate to Severe Hepatic Impairment"],"prefix":"10.1002","volume":"20","author":[{"given":"Dennis M.","family":"Grasela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Christofalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia D.","family":"Kollia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Noveck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"James A.","family":"Manning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank P.","family":"LaCreta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"CoyleEA.Evaluation of the activity of the newer fluoroquinolones against ciprofloxacin\u2010resistant Streptococcus pneumoniae (SP) [abstr]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_3_2","unstructured":"CastilloN. BarrigaG. AlarconN. RojasL. PeredoMA.Antibacterial activity of gatifloxacin (GAT) against Enterobacteriaceae and nonfermenting gram\u2010negative bacteria [abstr]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1128\/JCM.37.6.1999-2002.1999","article-title":"Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, e\u2010test comparisons, and quality control guidelines for H. influenzae","volume":"37","author":"Jones RN","year":"1999","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00114-X"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1128\/AAC.42.9.2459","article-title":"Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms","volume":"42","author":"Ednie LM","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00150-3"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.8.59S.35183"},{"key":"e_1_2_1_9_2","first-page":"S17","article-title":"Gatifloxacin vs clarithromycin in the management of acute sinusitis","volume":"20","author":"Fogarty C.","year":"1999","journal-title":"J Respir Dis"},{"key":"e_1_2_1_10_2","first-page":"S40","article-title":"Treating community\u2010acquired pneumonia with once daily gatifloxacin vs twice daily clarithromycin","volume":"20","author":"Ramirez JA","year":"1999","journal-title":"J Respir Dis"},{"key":"e_1_2_1_11_2","unstructured":"CoxCC MarburyTC PittmanWG et al.A multicenter comparison of gatifloxacin (GAT) 400 mg qd vs. ciprofloxacin (CIP) 500 mg bid in the treatment of complicated urinary tract infection (UTI) and pyelonephritis [abstr]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_12_2","unstructured":"TarshisG. MiskinBM JonesTM et al.Oral gatifloxacin (GAT) 400 mg qd vs. oral levofloxacin (LEV) 500 mg qd in the treatment of uncomplicated skin and soft tissue infections (SSTI) [abstr]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.8.49S.35186"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528909093045"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800600817"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.140"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1155\/1991\/68915"},{"key":"e_1_2_1_19_2","first-page":"1","article-title":"Sample size determination for bioequivalence assessment by means of confidence intervals","volume":"29","author":"Diletti E.","year":"1991","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/00401706.1975.10489282"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600710205"},{"key":"e_1_2_1_22_2","first-page":"409","volume-title":"Drugs and pharmaceutical sciences, vol 15, Pharmacokinetics","author":"Gibaldi M.","year":"1982"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01059549"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01059558"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.3790\/978-3-428-06689-6"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199700331-00006"},{"key":"e_1_2_1_27_2","first-page":"2414","volume-title":"Physicians' desk reference","year":"1999"},{"key":"e_1_2_1_28_2","unstructured":"StahlbergHJ GoehlerK. GuillaumeM. MignotA..Multiple\u2010dose pharmacokinetics and excretion balance of gatifloxacin a new fluoroquinolone antibiotic after oral administration to healthy Caucasian volunteers [abstr]. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto Canada September 28October 1 1997."},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199528020-00005"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.20.8.87S.35187","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.20.8.87S.35187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:45:40Z","timestamp":1761050740000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.20.8.87S.35187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,6]]},"references-count":28,"journal-issue":{"issue":"6P2","published-print":{"date-parts":[[2000,6]]}},"alternative-id":["10.1592\/phco.20.8.87S.35187"],"URL":"https:\/\/doi.org\/10.1592\/phco.20.8.87s.35187","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,6]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}